| CAS | 122018-58-0 |
| Sequence | H-His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-OH |
| Sequence Single | HSLGKWLGHPDKF |
| Molecular Formula | C72H104N20O17 |
| Molecular Weight | 1521.74 |
| Synonyms | (Ser140)-PLP (139-151) (depalmitoylated) (human, bovine, dog, mouse, rat), (Ser140)-Lipophilin (139-151) (depalmitoylated) (human, bovine, dog, mouse, rat) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Immunomodulating Agents|Multiple Sclerosis |
| Description | (Ser140)-Myelin Proteolipid Protein (139-151) (depalmitoylated) (human, bovine, dog, mouse, rat) also called (Ser140)-PLP (139-151) (depalmitoylated) (human, bovine, dog, mouse, rat), (Ser140)-Lipophilin (139-151) (depalmitoylated) (human, bovine, dog, mouse, rat), is fragment of myelin proteolipid protein, it is an encephalitogenic determinant, able to bind to diverse sets of T cell receptors. |
| References | 1. Epidermal growth factor suppresses nitric oxide and hydrogen peroxide production by keratinocytes. Potential role for nitric oxide in the regulation of wound healing. D.E.Heck et al., J. Biol. Chem., 267, 21277 (1992) 2. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. H.Waldner et al., Proc. Natl. Acad. Sci. USA, 97, 3412 (2000) 3. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. V.K.Tuohy et al., J. Immunol., 142, 1523 (1989) |